Skip to main content
OpenTrials
Enrolling by Invitation

NCT Number: NCT05284513

Collaborative Approach to Reach Everyone With Familial Hypercholesterolemia (CARE-FH)

Diagnosis rates of familial hypercholesterolemia (FH) are low in the United States, despite multiple guidelines and recommendations for screening and treatment of high cholesterol, to prevent heart attacks in those affected. Using a stepped-wedge design, the investigators plan to utilize tools from implementation science to improve uptake, acceptability, and sustainability of FH diagnostic programs in primary care settings. If successful, this study will provide tools generalizable to other health care systems to improve FH diagnosis rates.

Enrolling by Invitation

Interested in participating?

Request Info

Key information

About this study

Familial hypercholesterolemia (FH) is a common genetic disorder (prevalence 1 in 250) that requires lifelong sustained medical care. Evidence-based guidelines for screening and treatment for FH exist. These include universal screening of children ages 9-11, of adolescents ages 18-20, and of adults ages 40 and above; approved diagnostic tools including lipid panels and genetic testing; and recommendations for initiation of lipid lowering medication. FH diagnosis is currently made too late in life, often after a premature heart attack has occurred creating a care gap that results in excess cardiovascular morbidity and mortality. Diagnosing FH in the primary care setting would optimize treatment for individuals with FH and close this care gap. Utilizing tools from implementation science and human centered design, and by considering uptake, acceptability, and sustainability of programs related to FH care should improve earlier diagnosis. Implementation strategies that include insights from patients, clinicians, and healthcare systems are necessary. The long-term goal is to create an effective FH diagnosis program that is practical and sustainable in the real-world setting. The main objective of this project is to determine the uptake of an FH diagnosis program integrated into primary care practices to promote early identification of adult and pediatric patients that is generalizable to other healthcare settings. The research question is, does using a multi-level implementation strategy package, designed to address the specific needs of patients, clinicians, and healthcare systems, improve the diagnosis and activation of care management for individuals with FH. The specific aims are to: 1) to design a clinical trial to assess multi-level implementation strategies for improving FH diagnosis in an integrated health system, 2) compare FH diagnosis rates among primary care clinicians who receive the implementation strategy package versus those who do not, 3) to measure implementation success of an organized FH diagnosis program, and 4) to explore patient-related service and health outcomes related to an FH diagnosis program.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Primary care clinicians (pediatrician, community medicine, internal medicine) in the Geisinger Healthcare System

Exclusion criteria

  • None

Treatment and study plan

FH diagnosis program

Behavioral

Uptake of screening, diagnosis, and initiation of care management for FH

Implementation strategy package: Develop and implement tools for quality monitoring

Behavioral

EHR tools to order labs, record results, and document FH care

Implementation strategy package: Develop educational materials

Behavioral

Education regarding guidelines for identification and treatment of FH

Implementation strategy package: Conduct educational outreach visits

Behavioral

Continuing medical education (CME) material for FH that is presented to

Implementation strategy package: Intervene with clinicians and patients to enhance

Behavioral

Notify patients simultaneously with clinicians about the need for screening

Behavioral (e.g., Psychotherapy, Lifestyle Counseling) Implementation strategy package: Identify and prepare champions Clinical lipid champions

Behavioral

Clinical lipid champions

Implementation strategy package: Audit and provide feedback

Behavioral

Provide aggregate level feedback to clinics on diagnosing FH

Implementation strategy package: Stage implementation scale up

Behavioral

Develop the timeline for the stepped-wedge rollout to primary care

Primary outcomes

  1. FH diagnosis rate (Aim 2)

    Time frame: Up to 45 months

    FH diagnosis rate, is achieving both the scheduling of a clinic visit and evidence the clinician, at that visit, has completed evidence-based FH diagnostic evaluation, defined as completing one of: using the FH clinic note to document care, adding FH diagnosis on the problem list, using the FH smart-set (or ordered a genetic test for FH), making a referral to the lipid clinic, or starting a statin for an evidence-based indication

  2. Acceptability (Aim 3)

    Time frame: Month 9, 12, 18, 24, 30, 36, 42

    Clinician and patient satisfaction and self-efficacy with the FH diagnosis program

  3. Timeliness (Aim 4)

    Time frame: Up to 45 months

    Time to FH screen, time to diagnostic evaluation, time to statin initiation

Secondary outcomes

  1. Initiation medication use (Aim 2)

    Time frame: Up to 45 months

    Initiation of lipid lowering medication by healthcare clinician

  2. Lipid measurement (Aim 2)

    Time frame: Up to 45 months

    Order of a lipid panel

  3. Genetic testing (Aim 2)

    Time frame: Month 9, 12, 18, 24, 30, 36, 42

    Order of a genetic test for FH

  4. Problem list diagnosis of FH (Aim 2)

    Time frame: Up to 45 months

    Clinician adds diagnosis of FH to the patients problem list in the electronic health record

  5. FH smartset (Aim 2)

    Time frame: Month 9, 12, 18, 24, 30, 36, 42

    Clinician uses and completes all field of the FH smartset

  6. Best Practice Alert (Aim 2)

    Time frame: Up to 45 months

    Clinician adheres to and acts on recommendation in the Best Practice Alert

  7. FH Clinic Note (Aim 2)

    Time frame: Up to 45 months

    Clinician completes the FH clinic note

  8. Fidelity (Aim 3)

    Time frame: Up to 45 months

    Documentation of adaptations to the FH diagnosis program

  9. Cost (Aim 3)

    Time frame: Up to 45 months

    Cost to implement the implementation strategy package

  10. Function (Aim 4)

    Time frame: Up to 45 months

    Return of genetic result to patient (if ordered and patient undergoes testing)

  11. Function (Aim 4)

    Time frame: Up to 45 months

    Reduction in lipid level from baseline to end of the study period

  12. Function (Aim 4)

    Time frame: Up to 45 months

    Patient side effects to medications

Sponsors and collaborators

Lead sponsor

Geisinger Clinic

Other

Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

Registry information

Acronym: CARE-FH

Important dates

Study start
2022
Primary completion
2027
Study completion
2027
First posted
Mar 17, 2022
Registry last updated
Dec 22, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.